

Oriana Ciani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4122773/publications.pdf>

Version: 2024-02-01

91
papers

2,161
citations

201674

27
h-index

254184

43
g-index

95
all docs

95
docs citations

95
times ranked

2987
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to COVID-19: was Italy (un)prepared?. Health Economics, Policy and Law, 2022, 17, 1-13.	1.8	46
2	Lung cancer stage distribution from before COVID-19 through 18 months of the pandemic: the experience of a large-volume oncological referral centre. European Journal of Surgical Oncology, 2022, 48, 470-471.	1.0	5
3	An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Social Science and Medicine, 2022, 292, 114519.	3.8	29
4	The Importance of Using the Appropriate Model for Systematic Reviews and Meta-analysesâ€”Reply. JAMA Internal Medicine, 2022, 182, 357.	5.1	0
5	Coverage with evidence development for medical devices in Europe: Can practice meet theory?. Health Economics (United Kingdom), 2022, 31, 179-194.	1.7	6
6	Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps. Health Economics (United Kingdom), 2022, 31, 73-97.	1.7	13
7	Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence. Health Economics (United Kingdom), 2022, 31, 44-72.	1.7	9
8	Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. International Journal of Technology Assessment in Health Care, 2021, 37, e62.	0.5	14
9	Distinguishing features in the assessment of mHealth apps. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 521-526.	1.4	32
10	Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies. Medical Decision Making, 2021, 41, 439-452.	2.4	21
11	Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies. Health Policy, 2021, 125, 602-608.	3.0	20
12	Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges. European Journal of Health Economics, 2021, 22, 1253-1273.	2.8	13
13	Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. Cost Effectiveness and Resource Allocation, 2021, 19, 35.	1.5	11
14	Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies. Value in Health, 2021, 24, 1045-1058.	0.3	14
15	Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments. Journal of Clinical Epidemiology, 2021, 136, 26-36.	5.0	17
16	The Net Benefit of a treatment should take the correlation between benefits and harms into account. Journal of Clinical Epidemiology, 2021, 137, 148-158.	5.0	6
17	Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. BMJ, The, 2021, 374, n2191.	6.0	19
18	Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials. Npj Digital Medicine, 2021, 4, 144.	10.9	24

#	ARTICLE	IF	CITATIONS
19	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 1575.	5.1	28
20	The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?. <i>Cancer Management and Research</i> , 2021, Volume 13, 8457-8471.	1.9	10
21	An Electronic Patient-Reported Outcome Mobile App for Data Collection in Type A Hemophilia: Design and Usability Study. <i>JMIR Formative Research</i> , 2021, 5, e25071.	1.4	5
22	Introduction to economic evaluation and health technology assessment. , 2020, , 789-794.		1
23	Health technology assessment of medical devices. , 2020, , 795-798.		1
24	Measuring Value in Health Care: A Comparative Analysis of Value-based Frameworks. <i>Clinical Therapeutics</i> , 2020, 42, 34-43.	2.5	18
25	Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective. <i>Expert Review of Medical Devices</i> , 2020, 17, 993-1006.	2.8	15
26	Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines. <i>Pharmacoeconomics</i> , 2020, 38, 1055-1070.	3.3	33
27	A scoping review of core outcome sets and their "mapping"™ onto real-world data using prostate cancer as a case study. <i>BMC Medical Research Methodology</i> , 2020, 20, 41.	3.1	13
28	Value Lies in the Eye of the Patients: The Why, What, and How of Patient-reported Outcomes Measures. <i>Clinical Therapeutics</i> , 2020, 42, 25-33.	2.5	32
29	Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data. <i>Statistics in Medicine</i> , 2020, 39, 1103-1124.	1.6	14
30	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. <i>Frontiers in Public Health</i> , 2020, 8, 612410.	2.7	9
31	Harnessing Digital Health Technologies During and After the COVID-19 Pandemic: Context Matters. <i>Journal of Medical Internet Research</i> , 2020, 22, e21815.	4.3	45
32	Value-based healthcare: Il nuovo approccio di AIFA alla determinazione multidimensionale del valore. <i>Global & Regional Health Technology Assessment</i> , 2020, 7, 9-13.	0.1	1
33	PNS183 WHAT METHODS ARE APPLIED IN ASSESSESSING THE CLINICAL AND COST EFFECTIVENESS OF HEALTH TECHNOLOGIES BASED ON THE USE OF SURROGATE OUTCOMES: A COMPARISON OF EVALUATION REPORTS ACROSS INTERNATIONAL HEALTH TECHNOLOGY ASSESSMENT AGENCIES. <i>Value in Health</i> , 2019, 22, S316.	0.3	0
34	Impact of Exercise Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1430-1443.	2.8	172
35	Exercise training for chronic heart failure (ExTraMATCH II): Why all data are not equal. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1229-1231.	1.8	3
36	Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. <i>BMJ Open</i> , 2019, 9, e025483.	1.9	22

#	ARTICLE	IF	CITATIONS
37	Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis. <i>Health Technology Assessment</i> , 2019, 23, 1-98.	2.8	34
38	The impacts of diabetes research from 31 European Countries in 2002 to 2013. <i>Research Evaluation</i> , 2018, 27, 270-282.	2.6	6
39	Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 209-221.	1.4	5
40	Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study. <i>BMC Medicine</i> , 2018, 16, 45.	5.5	10
41	PCV8 - IMPACT OF EXERCISE-BASED REHABILITATION IN PATIENTS WITH HEART FAILURE (EXTRAMATCH II) ON EXERCISE CAPACITY AND HEALTH-RELATED QUALITY OF LIFE: A META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM RANDOMISED TRIALS. <i>Value in Health</i> , 2018, 21, S94.	0.3	2
42	Clinical Core Outcomes Sets in Real World Data. <i>Value in Health</i> , 2018, 21, S112.	0.3	0
43	Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials. <i>European Journal of Heart Failure</i> , 2018, 20, 1735-1743.	7.1	125
44	HEALTH TECHNOLOGY ASSESSMENT METHODS GUIDELINES FOR MEDICAL DEVICES: HOW CAN WE ADDRESS THE GAPS? THE INTERNATIONAL FEDERATION OF MEDICAL AND BIOLOGICAL ENGINEERING PERSPECTIVE. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 276-289.	0.5	28
45	Validation of Exercise Capacity as a Surrogate Endpoint in Exercise-Based Rehabilitation for Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 596-604.	4.1	47
46	Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. <i>BMC Cancer</i> , 2018, 18, 715.	2.6	15
47	Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 15.	1.5	3
48	The evaluation of medical devices: are we getting closer to solve the puzzle? A review of recent trends. <i>IFMBE Proceedings</i> , 2018, , 916-919.	0.3	2
49	Balneotherapy in knee osteoarthritis: a cost/effectiveness analysis alongside an italian randomized controlled clinical trial. <i>Boletín De La Sociedad Española De Hidrología Médica</i> , 2018, 33, 61-62.	0.0	0
50	Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Value in Health</i> , 2017, 20, 336-344.	0.3	29
51	Linking the Regulatory and Reimbursement Processes for Medical Devices: The Need for Integrated Assessments. <i>Health Economics (United Kingdom)</i> , 2017, 26, 13-29.	1.7	37
52	A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement. <i>Health Economics (United Kingdom)</i> , 2017, 26, 46-69.	1.7	21
53	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. <i>Value in Health</i> , 2017, 20, 487-495.	0.3	101
54	European diabetes research and its funding, 2002-2013. <i>Diabetic Medicine</i> , 2017, 34, 1354-1360.	2.3	14

#	ARTICLE	IF	CITATIONS
55	Mudâ€Bath Therapy in Addition to Usual Care in Bilateral Knee Osteoarthritis: An Economic Evaluation Alongside a Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2017, 69, 966-972.	3.4	34
56	A randomized, openâ€label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. <i>Neurourology and Urodynamics</i> , 2017, 36, 1178-1186.	1.5	49
57	PP100 Economic Evaluation Of A New Non-Antibiotic First-line Treatment Of Recurrent Urinary Tract Infections. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 118-119.	0.5	0
58	Results Of Individual Participant Data Meta-Analysis VS Aggregate Data Meta-Analysis Of RCTS Of Exercise Rehabilitation In Chronic Heart Failure. <i>Value in Health</i> , 2017, 20, A767.	0.3	0
59	Non-communicable diseases: mapping research funding organisations, funding mechanisms and research practices in Italy and Germany. <i>Health Research Policy and Systems</i> , 2017, 15, 85.	2.8	0
60	Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested caseâ€control study. <i>BMJ Open</i> , 2016, 6, e009669.	1.9	53
61	Decision Uncertainty and Need for Further Research: A Case-Study in Fenestrated Endovascular Aneurysm Repair for Complex Abdominal Aortic Aneurysms. <i>Value in Health</i> , 2016, 19, A356-A357.	0.3	0
62	Diffusion of Trans-Arterial Radioembolization for The Treatment of Intermediate-Advanced Hepatocellular Carcinoma in Italy: A Budget Impact Analysis. <i>Value in Health</i> , 2016, 19, A687.	0.3	0
63	Cost-Effectiveness Analysis of A Potential Treatment Introduction for Anorexia-Cachexia in Non-Small Cell Lung Cancer Patients. <i>Value in Health</i> , 2016, 19, A729-A730.	0.3	0
64	Construction of Inflatable Lungs to Simulate Respiratory Motion in Myocardial Perfusion Imaging. <i>IFMBE Proceedings</i> , 2016, , 1337-1341.	0.3	2
65	Current and Future Trends in the HTA of Medical Devices. <i>IFMBE Proceedings</i> , 2016, , 1345-1348.	0.3	6
66	Mapping research activity on mental health disorders in Europe: study protocol for the Mapping_NCD project. <i>Health Research Policy and Systems</i> , 2016, 14, 39.	2.8	5
67	Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 516-516.	46.4	32
68	Validation of surrogate end points for overall survival in advanced colorectal cancer: A harmonized approach is needed. <i>Journal of Clinical Epidemiology</i> , 2016, 70, 277-278.	5.0	2
69	Comparing Drug and Nondrug Technologies in Comparative Effectiveness Research. , 2016, , 275-290.		1
70	De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making. <i>Health Policy and Technology</i> , 2016, 5, 47-64.	2.5	38
71	Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. <i>Oncotarget</i> , 2016, 7, 72343-72355.	1.8	57
72	HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES: A SURVEY OF NON-EUROPEAN UNION AGENCIES. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 154-165.	0.5	49

#	ARTICLE	IF	CITATIONS
73	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 95-117.	2.5	27
74	Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 833-842.	5.0	48
75	Comparing Drug and Non-drug Technologies in Comparative Effectiveness Research. , 2015, , 1-17.		0
76	The role of health technology assessment bodies in shaping drug development. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2273.	4.3	39
77	VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 312-324.	0.5	69
78	Exercise training for chronic heart failure (ExTraMATCH II): Protocol for an individual participant data meta-analysis. <i>International Journal of Cardiology</i> , 2014, 174, 683-687.	1.7	23
79	SURROGATE, FRIEND OR FOE? THE NEED FOR CASE STUDIES OF THE USE OF SURROGATE OUTCOMES IN COST-EFFECTIVENESS ANALYSES. <i>Health Economics (United Kingdom)</i> , 2013, 22, 251-252.	1.7	5
80	An Economic Perspective on Urinary Tract Infection: The "Costs of Resignation". <i>Clinical Drug Investigation</i> , 2013, 33, 255-261.	2.2	69
81	Validation of Surrogate Endpoints in Advanced Solid Tumours: Systematic Review of Statistical Methods, Results, and Implications for Policy Makers. <i>Value in Health</i> , 2013, 16, A327.	0.3	1
82	Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. <i>BMJ, The</i> , 2013, 346, f457-f457.	6.0	119
83	Determinants of demand for total hip and knee arthroplasty: a systematic literature review. <i>BMC Health Services Research</i> , 2012, 12, 225.	2.2	114
84	Diffusion and use of health technology assessment in policy making: What lessons for decentralised healthcare systems?. <i>Health Policy</i> , 2012, 108, 194-202.	3.0	39
85	PA2 Hospital-Based HTA in Italy: Diffusion and Potential Impact. <i>Value in Health</i> , 2012, 15, A283.	0.3	3
86	PRM60 General Methodological Issues in Cost-Effectiveness Analysis Inspired by the Assessment of Dasatinib, Nilotinib and Imatinib for 1st- Line Chronic Myeloid Leukaemia. <i>Value in Health</i> , 2012, 15, A471.	0.3	0
87	Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.. <i>Health Technology Assessment</i> , 2012, 16, iii-iv, 1-277.	2.8	49
88	A more evidence based approach to the use of surrogate end points in policy making. <i>BMJ: British Medical Journal</i> , 2011, 343, d6498-d6498.	2.3	3
89	Method for Movement and Gesture Assessment (MMGA) in Ergonomics. <i>Lecture Notes in Computer Science</i> , 2009, , 591-598.	1.3	17
90	Pervasive technology in Neonatal Intensive Care Unit: A prototype for newborns unobtrusive monitoring. , 2008, 2008, 1292-5.		5

#	ARTICLE	IF	CITATIONS
91	Need for better reporting of trials with surrogate endpoints: SPIRIT CONSORT-SURROGATE extensions. Journal of Epidemiology and Community Health, 0, , jech-2022-219294.	3.7	2